[go: up one dir, main page]

WO2007138557A3 - Controlled-release multiple unit pharmaceutical compositions - Google Patents

Controlled-release multiple unit pharmaceutical compositions Download PDF

Info

Publication number
WO2007138557A3
WO2007138557A3 PCT/IB2007/052037 IB2007052037W WO2007138557A3 WO 2007138557 A3 WO2007138557 A3 WO 2007138557A3 IB 2007052037 W IB2007052037 W IB 2007052037W WO 2007138557 A3 WO2007138557 A3 WO 2007138557A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled
multiple unit
pharmaceutical compositions
release multiple
unit pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/052037
Other languages
French (fr)
Other versions
WO2007138557A2 (en
Inventor
Sankar Ramakrishnan
Narayanan Badri Viswanathan
Ashok Rampal
Rajesh S Shear
Sumit Madan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2007138557A2 publication Critical patent/WO2007138557A2/en
Publication of WO2007138557A3 publication Critical patent/WO2007138557A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a controlled-release multiple unit formulation and processes of preparation thereof. The formulation comprises (i) a core unit of an inert material; and (ii) a coating layer comprising a mixture of a pharmaceutically active ingredient, at least one water-insoluble polymer, at least one hydrophilic polymer and at least one water-soluble component.
PCT/IB2007/052037 2006-05-30 2007-05-30 Controlled-release multiple unit pharmaceutical compositions Ceased WO2007138557A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1308DE2006 2006-05-30
IN1308/DEL/2006 2006-05-30

Publications (2)

Publication Number Publication Date
WO2007138557A2 WO2007138557A2 (en) 2007-12-06
WO2007138557A3 true WO2007138557A3 (en) 2008-02-14

Family

ID=38645782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/052037 Ceased WO2007138557A2 (en) 2006-05-30 2007-05-30 Controlled-release multiple unit pharmaceutical compositions

Country Status (1)

Country Link
WO (1) WO2007138557A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058869A1 (en) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049374A (en) * 1989-11-28 1991-09-17 Dansereau Richard J Oral (coated bead) dosage form for sodium iodide I-131
DE4400295A1 (en) * 1993-01-12 1994-07-14 Freunt Ind Co Ltd Spherical lactose granule
WO2000000179A1 (en) * 1998-06-27 2000-01-06 Won Jin Biopharma Co., Ltd. Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof
US6221396B1 (en) * 1998-07-17 2001-04-24 Development Center For Biotechnology Oral cisapride dosage forms with an extended duration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049374A (en) * 1989-11-28 1991-09-17 Dansereau Richard J Oral (coated bead) dosage form for sodium iodide I-131
DE4400295A1 (en) * 1993-01-12 1994-07-14 Freunt Ind Co Ltd Spherical lactose granule
WO2000000179A1 (en) * 1998-06-27 2000-01-06 Won Jin Biopharma Co., Ltd. Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof
US6221396B1 (en) * 1998-07-17 2001-04-24 Development Center For Biotechnology Oral cisapride dosage forms with an extended duration

Also Published As

Publication number Publication date
WO2007138557A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2008132712A3 (en) Combination pharmaceutical compositions
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008022932A3 (en) Controlled release system and method for manufacturing the same
UA95993C2 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2008060963A3 (en) Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2010081824A3 (en) Active coating of pharmaceutical dosage forms
WO2009059701A3 (en) Sustained release tablets with hydromorphone
WO2007146293A3 (en) Improved composition and method for taste masking
WO2012022919A3 (en) Nalbuphine-based formulations and uses thereof
EP1177788A3 (en) Pharmaceutical composition of fluoxetin in coated dispersible tablets and process for its manufacture
WO2005027843A3 (en) Chronotherapeutic dosage forms
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
MX341015B (en) Extended-release dosage form.
WO2007014124A3 (en) High drug load formulations and dosage forms
BRPI0412354A (en) prolonged release formulation for venlafaxine hydrochloride
WO2007144080A3 (en) Combination antidepressants wafer
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
WO2008122994A3 (en) Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
WO2007138557A3 (en) Controlled-release multiple unit pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736053

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07736053

Country of ref document: EP

Kind code of ref document: A2